Skip to main content
Erschienen in: Medical Oncology 11/2014

01.11.2014 | Original Paper

TRAF6 is over-expressed in pancreatic cancer and promotes the tumorigenicity of pancreatic cancer cells

verfasst von: Yefei Rong, Dansong Wang, Wenchuan Wu, Dayong Jin, Tiantao Kuang, Xiaolin Ni, Lei Zhang, Wenhui Lou

Erschienen in: Medical Oncology | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

Pancreatic cancer is one of the most lethal malignancies, with a poor response to chemotherapy and therefore it is important to identify novel therapeutic targets. TNF receptor-associated factor 6 (TRAF6) , a regulator of NF-κB signaling, has been found recently to be involved in tumorigenesis. However, its function in pancreatic cancer remains poorly understood. Here, we found that the expression of TRAF6 was up-regulated in pancreatic cancer tissues. Moreover, over-expression of TRAF6 in pancreatic cancer cells promoted cell proliferation and migration, whereas down-regulation of TRAF6 impaired the tumorigenicity of pancreatic cancer cells in vitro and in vivo. Mechanistically, TRAF6 regulated the expression of multiple genes involved in cell growth, apoptosis and migration. Our results suggested several important roles of TRAF6 in the pathogenesis of pancreatic cancer. TRAF6 might therefore represent a potential therapeutic target.
Literatur
2.
Zurück zum Zitat Morganti AG, Massaccesi M, Caravatta L, et al. A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol. 2010;17:194–205.PubMedCrossRef Morganti AG, Massaccesi M, Caravatta L, et al. A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol. 2010;17:194–205.PubMedCrossRef
3.
Zurück zum Zitat Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancerbinding protein Nf-kappa B by a posttranslational mechanism. Cell. 1986;47:921–8.PubMedCrossRef Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancerbinding protein Nf-kappa B by a posttranslational mechanism. Cell. 1986;47:921–8.PubMedCrossRef
4.
Zurück zum Zitat Baldwin AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1986;14:649–83.CrossRef Baldwin AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1986;14:649–83.CrossRef
5.
Zurück zum Zitat Farrow B, Evers BM. Inflammation and the development of pancreatic cancer. Surg Oncol. 2002;10:153–69.PubMedCrossRef Farrow B, Evers BM. Inflammation and the development of pancreatic cancer. Surg Oncol. 2002;10:153–69.PubMedCrossRef
6.
Zurück zum Zitat Wang W, Abbruzzese JL, Evans DB, et al. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res. 1999;5:119–27.PubMed Wang W, Abbruzzese JL, Evans DB, et al. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res. 1999;5:119–27.PubMed
7.
Zurück zum Zitat Chandler NM, Canete JJ, Callery MP. Increased expression of Nfkappa B subunits in human pancreatic cancer cells. J Surg Res. 2004;118:9–14.PubMedCrossRef Chandler NM, Canete JJ, Callery MP. Increased expression of Nfkappa B subunits in human pancreatic cancer cells. J Surg Res. 2004;118:9–14.PubMedCrossRef
8.
Zurück zum Zitat Cascinu S, Scartozzi M, Carbonari G, et al. COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin. Am J Clin Oncol. 2007;30:526–30.PubMedCrossRef Cascinu S, Scartozzi M, Carbonari G, et al. COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin. Am J Clin Oncol. 2007;30:526–30.PubMedCrossRef
9.
Zurück zum Zitat Weichert W, Boehm M, Gekeler V, et al. High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer. 2007;97:523–30.PubMedCrossRefPubMedCentral Weichert W, Boehm M, Gekeler V, et al. High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer. 2007;97:523–30.PubMedCrossRefPubMedCentral
10.
Zurück zum Zitat Pan X, Arumugam T, Yamamoto T, et al. Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res. 2008;14:8143–51.PubMedCrossRef Pan X, Arumugam T, Yamamoto T, et al. Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res. 2008;14:8143–51.PubMedCrossRef
11.
Zurück zum Zitat Kong R, Sun B, Jiang H, et al. Downregulation of nuclear factor-kappaB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer. Cancer Lett. 2010;291:90–8.PubMedCrossRef Kong R, Sun B, Jiang H, et al. Downregulation of nuclear factor-kappaB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer. Cancer Lett. 2010;291:90–8.PubMedCrossRef
12.
Zurück zum Zitat Fujioka S, Sclabas GM, Schmidt C, et al. Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res. 2003;9:346–54.PubMed Fujioka S, Sclabas GM, Schmidt C, et al. Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res. 2003;9:346–54.PubMed
13.
Zurück zum Zitat Daniel TS, William WL, Sophie D. TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer. J Clin Investig. 2011;121(10):4095–105.CrossRef Daniel TS, William WL, Sophie D. TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer. J Clin Investig. 2011;121(10):4095–105.CrossRef
14.
Zurück zum Zitat Yao Feng, Han Qingqi, Zhong Chenxi, Zhao Heng. TRAF6 promoted the tumorigenicity of esophageal squamous cell carcinoma. Tumor Biol. 2013;34(5):3201–7.CrossRef Yao Feng, Han Qingqi, Zhong Chenxi, Zhao Heng. TRAF6 promoted the tumorigenicity of esophageal squamous cell carcinoma. Tumor Biol. 2013;34(5):3201–7.CrossRef
15.
Zurück zum Zitat Schneider M, Zimmermann AG, Roberts RA, et al. The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-kappaB. Nat Immunol. 2012;13:823–31.PubMedCrossRefPubMedCentral Schneider M, Zimmermann AG, Roberts RA, et al. The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-kappaB. Nat Immunol. 2012;13:823–31.PubMedCrossRefPubMedCentral
16.
Zurück zum Zitat Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell. 2010;17:135–47.PubMedCrossRef Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell. 2010;17:135–47.PubMedCrossRef
17.
Zurück zum Zitat Arlt A, Gehrz A, Muerkoster S, et al. Role of NFkappaB and Akt/PI3 K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene. 2003;22:3243–51.PubMedCrossRef Arlt A, Gehrz A, Muerkoster S, et al. Role of NFkappaB and Akt/PI3 K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene. 2003;22:3243–51.PubMedCrossRef
18.
Zurück zum Zitat Elisa G, Wang QY, Amir A, et al. Role of cyb5a in pancreatic cancer prognosis and autophagy modulation. J Natl Cancer Inst. 2014;106:1–12.CrossRef Elisa G, Wang QY, Amir A, et al. Role of cyb5a in pancreatic cancer prognosis and autophagy modulation. J Natl Cancer Inst. 2014;106:1–12.CrossRef
19.
Zurück zum Zitat Sorrentino A, Thakur N, Grimsby S, et al. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol. 2008;10:1199–207.PubMedCrossRef Sorrentino A, Thakur N, Grimsby S, et al. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol. 2008;10:1199–207.PubMedCrossRef
20.
Zurück zum Zitat Ostapoff KT, Kutluk Cenik B, Wang M, et al. Neutralizing murine TGFβR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis. Cancer Res. 2014 [Epub ahead of print]. Ostapoff KT, Kutluk Cenik B, Wang M, et al. Neutralizing murine TGFβR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis. Cancer Res. 2014 [Epub ahead of print].
Metadaten
Titel
TRAF6 is over-expressed in pancreatic cancer and promotes the tumorigenicity of pancreatic cancer cells
verfasst von
Yefei Rong
Dansong Wang
Wenchuan Wu
Dayong Jin
Tiantao Kuang
Xiaolin Ni
Lei Zhang
Wenhui Lou
Publikationsdatum
01.11.2014
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 11/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0260-9

Weitere Artikel der Ausgabe 11/2014

Medical Oncology 11/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.